13therapeutics, Inc.

P13 has demonstrated efficacy in significantly reducing serum inflammatory cytokines and enhancing survival in preclinical models of systemic inflammation.  These studies suggest a potential application of P13 and the derivative peptides in treating inflammatory diseases associated with a "cytokine storm".